Medicines New Zealand Unveils 2022 Transfer of Value Reports to Enhance Transparency

By Danélia Botes

August 30, 2023

Medicines New Zealand is delighted to announce the launch of the 2022 Transfer of Value reports. These reports, representing the organisation’s second annual publication, offer a transparent snapshot of the financial interactions between biopharmaceutical companies and healthcare professionals. This initiative underscores our unwavering commitment to transparency and ethical standards within the industry.

Dr Graeme Jarvis, CEO of Medicines New Zealand, remarked on the release, “This information is what the joint project between industry and healthcare practitioners was designed to deliver.”

The reports aim to shed light on the financial relationships and interactions between biopharmaceutical companies and healthcare professionals. They seek to bolster transparency and uphold ethical standards within the industry.

“Public reporting of payments made by the biopharmaceutical industry to healthcare professionals is the right thing to do from a transparency perspective,” said Dr Jarvis. “This commitment allows patients and the public to gain insight into the nature of these interactions and have confidence in the ethical standards and patient-centric approach of healthcare professionals in New Zealand.”

The 2022 Transfer of Value reports provide a comprehensive overview of the financial interactions between Medicines New Zealand member companies and healthcare professionals. These interactions include sponsorships for healthcare providers to attend medical education events and conferences, which ultimately benefit patient care and contribute to the continuous improvement of healthcare practices.

Medicines New Zealand invites all interested parties to access the Transfer of Value reports from its member companies. The reports serve as a valuable resource for those seeking a deeper understanding of the financial relationships that drive advancements in patient care.

Reference url

Recent Posts

South African National Health Insurance Bill

High Court on South African National Health Insurance Bill

📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill

Global Perspective on Orphan Medicines

A Global Perspective on Orphan Medicines and Rare Diseases

Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here


The Impact of Universal Health Coverage on Poverty Reduction in Low and Middle-Income Countries

📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.